Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Report 2026

The calcitonin gene-related peptide (cgrp) inhibitors market size has grown strongly in recent years. It will grow from $3.14 billion in 2025 to $3.45 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to rising prevalence of migraine disorders, limitations of conventional migraine drugs, growing clinical validation of CGRP pathway, increased neurologist adoption, favorable reimbursement in developed markets.

The calcitonin gene-related peptide (cgrp) inhibitors market size is expected to see strong growth in the next few years. It will grow to $5.02 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to expanding chronic migraine patient pool, pipeline expansion of oral CGRP inhibitors, increasing demand for long-term migraine prevention, improved patient adherence to targeted therapies, growing access in emerging markets. Major trends in the forecast period include growing adoption of targeted migraine therapies, increasing shift toward preventive migraine treatment, rising preference for non-opioid pain management, expansion of oral CGRP small molecule inhibitors, increasing awareness and diagnosis of chronic migraine.

The rising prevalence of migraine is expected to drive the growth of the calcitonin gene-related peptide (CGRP) inhibitors market in the coming years. Migraine is a severe headache, often characterized by throbbing pain on one side of the head, and is commonly accompanied by nausea, vomiting, and sensitivity to light and sound. This increase is largely linked to rising stress levels, as chronic stress activates neural pathways associated with migraine onset. CGRP inhibitors support migraine management by providing a targeted, preventative approach compatible with both acute and chronic care regimens. They reduce the frequency and severity of headaches through efficient CGRP receptor blockade, improving patients’ daily functioning and overall well-being. For example, in January 2023, a report by the National Library of Medicine, a US-based health information institution, indicated that the global prevalence of migraine ranges from 14% to 15%, contributing to 4.9% of the global disease burden. Consequently, the growing prevalence of migraine is fueling the expansion of the CGRP inhibitors market.

Leading companies in the calcitonin gene-related peptide (CGRP) inhibitors market are focusing on developing innovative therapies, such as CGRP receptor antagonists, to enhance migraine treatment efficacy, expand therapeutic indications, and provide more convenient administration options, including oral and intranasal formulations. CGRP receptor antagonists are drugs that block the calcitonin gene-related peptide (CGRP) receptor to inhibit migraine-related pain signaling. For example, in April 2023, AbbVie Inc., a US-based biotech company, received U.S. Food and Drug Administration (FDA) approval for QULIPTA (atogepant) to treat chronic migraine in adults. QULIPTA is an oral CGRP receptor antagonist that works by blocking CGRP receptors involved in migraine pathophysiology, thereby helping to prevent migraine attacks.

In August 2024, Organon, a US-based healthcare company specializing in women’s health, expanded its commercialization agreement with Eli Lilly and Company to become the sole distributor and promoter of Emgality (galcanezumab) in 11 additional markets. Through this agreement, Organon aims to strengthen its migraine treatment portfolio and broaden global patient access by combining Lilly’s marketed therapy with Organon’s commercialization capabilities. Eli Lilly and Company, based in the US, develops and markets Emgality, a humanized monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) for the preventive treatment of migraine.

Major companies operating in the calcitonin gene-related peptide (cgrp) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.

North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (cgrp) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the calcitonin gene-related peptide (cgrp) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the calcitonin gene-related peptide (CGRP) inhibitors market by increasing the cost of imported biologic APIs, formulation excipients, and drug delivery components used in monoclonal antibodies and oral CGRP inhibitors. These impacts are most pronounced in monoclonal antibody segments and preventive migraine treatments, particularly in North America and Europe where global API sourcing is common. Asia-Pacific manufacturers have faced supply chain delays and cost pressures due to trade dependencies. However, tariffs have encouraged localized biologics manufacturing and regional API production, supporting long-term supply resilience.

The calcitonin gene-related peptide (cgrp) inhibitors market research report is one of a series of new reports that provides calcitonin gene-related peptide (cgrp) inhibitors market statistics, including calcitonin gene-related peptide (cgrp) inhibitors industry global market size, regional shares, competitors with a calcitonin gene-related peptide (cgrp) inhibitors market share, detailed calcitonin gene-related peptide (cgrp) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the calcitonin gene-related peptide (cgrp) inhibitors industry. This calcitonin gene-related peptide (cgrp) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Calcitonin gene-related peptide (CGRP) inhibitors are drugs that block the CGRP pathway, which plays a role in transmitting pain and dilating blood vessels in the brain. These inhibitors help reduce the frequency and severity of migraines and are used to treat patients with chronic or episodic migraines.

The main types of CGRP inhibitors include monoclonal antibodies, small molecules, and peptides. Monoclonal antibodies are laboratory-produced molecules designed to bind specifically to a single target, such as a protein or receptor in the body. Their mechanisms of action include anti-CGRP ligand therapies and CGRP receptor antagonists. Routes of administration include oral, nasal, and intravenous delivery. Treatments are classified as preventive or acute migraine therapies. End users include hospitals, specialty clinics, mail-order pharmacies, and retail pharmacies.

The calcitonin gene-related peptide (CGRP) inhibitors market consists of sales of aimovig, emgality, ubrogepant, rimegepant, atogepant, and ajovy. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.